Company Profile of DONGBANG FUTURE TECH & LIFE CO., LTD.

Dongbang FTL has committed to producing high-quality pharmaceuticals in the fields of synthetic API(Active Pharmaceutical Ingredients), natural API, and finished pharmaceuticals products, all based on the core value of 'quality' and backed by exceptional technical expertise. Chemical API In the area of synthetic API, we have received GMP certifications from the Korea FDA, Japan's PMDA, Australia's TGA, and France's ANSM. Currently, we are supplying a wide range of API, such as anti-inflammatory analgesics, antihypertensive drugs, cardiovascular disease treatments, diabetes medications, and urinary system treatments, to global pharmaceuticals. We have firmly established our position in the Japanese market with over 20 J-DMF(Japanese Drug Master Files) products, and we are expanding our business in Europe with more than 10 EU-DMF(European Union Drug Master Files) products. Moreover, we are currently conducting 35 CMC(Chemistry, Manufacturing and Controls) and CDMO (Contract Development and Manufacturing Organization) projects in collaboration with leading domestic and international global pharmaceutical and biotech companies and research institutions. In addition, based on our technology specialized in molecule structure design and molecule synthesis, we are expanding investment in our own new drug development and making tangible results using PROTAC technology. Finished Drug For finished pharmaceutical product business, we are mainly focused on tablets, soft capsule and hard capsule formulations supplying products like anti-inflammatory analgesics, neurotic disorder treatments, and vitamin supplements both domestically and internationally.